Celestica Inc vs Cytokinetics Inc — how do they compare? Celestica Inc trades at $314.95 (market cap $39.77B), while Cytokinetics Inc trades at $76.66 (market cap $10.78B). The key difference: Celestica Inc is far larger — about 3.7× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Celestica Inc nearer its low. Which is the better fit depends on your goals.
| CLS | CYTK | |
|---|---|---|
Market Cap | $39.77B | $10.78B |
Sector | Technology | Technology |
52-Week High | $472.40 | $87.26 |
52-Week Low | $181.34 | $34.31 |
Enterprise Value | $40.05B | $10.88B |
Signals from Pluang's Aura AI — not financial advice
CLS trades at $317.83, up 1.05% today, with strong earnings momentum after beating estimates in Q4 2025, Q1 2026, and Q2 2026. Technical indicators show a bearish trend with support at $309 and resistance at $323. The company reported $12.39B revenue in 2025 with net income of $832.5M, supported by robust cash flow from operations of $659.5M. Recent news highlights a $3B equity offering to fund AI infrastructure growth, though it may cause near-term dilution.
Outlook is positive with analyst consensus price target of $455.33 (43% upside), but risks include equity dilution from the offering and premium valuations (P/E 36.4). Growth catalysts are strong AI-driven demand and expanding partnerships, making CLS a compelling pick for investors seeking exposure to data center infrastructure, albeit with volatility near-term.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Trailing returns across standard periods
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →